


LEGEND-T2DM Evidence Dissemination Summary

Target: **exenatide**, Comparator: **empagliflozin** Outcome: **Bone fracture** Subgroup: **All**

How Often? (Incidence rates in the PS-matched target cohorts)

| Data source | Persons exposed | Person-time (yrs) | Nr. of outcomes | IR (/1,000 PY) |
|------------------|-----------------|-------------------|-----------------|----------------|
| CCAE | 2,290 | 1,280 | 27 | 21.09 |
| Clinformatics | 1,876 | 1,133 | 33 | 29.11 |
| DA Germany | - | - | - | - |
| LDP France | - | - | - | - |
| MDCD | 596 | 291 | 12 | 41.27 |
| MDCR | 161 | 59 | <5 | <84.55 |
| Open Claims | 0 | 0 | 0 | NaN |
| Optum EHR | 2,664 | 1,108 | 12 | 10.83 |
| Veterans Affairs | - | - | - | - |

How Reliable Are the Effect Estimates? (Objective diagnostics)



What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)

